Kamada (NASDAQ:KMDA) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Kamada (NASDAQ:KMDAGet Rating) in a report released on Monday morning. The brokerage issued a buy rating on the biotechnology company’s stock.

Kamada Price Performance

KMDA stock opened at $4.30 on Monday. Kamada has a 12 month low of $4.11 and a 12 month high of $6.96. The company has a current ratio of 2.39, a quick ratio of 1.09 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $4.48 and a 200 day moving average price of $4.68. The stock has a market cap of $192.64 million, a PE ratio of -18.69 and a beta of 0.94.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its position in Kamada by 32.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 68,889 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 16,886 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Kamada by 151.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 37,518 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 22,576 shares during the period. Vanguard Group Inc. lifted its stake in shares of Kamada by 3.1% in the 1st quarter. Vanguard Group Inc. now owns 779,451 shares of the biotechnology company’s stock valued at $4,302,000 after purchasing an additional 23,768 shares during the period. Citigroup Inc. lifted its stake in shares of Kamada by 2,620.0% in the 1st quarter. Citigroup Inc. now owns 36,938 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 35,580 shares during the period. Finally, Acadian Asset Management LLC raised its position in Kamada by 7.2% during the first quarter. Acadian Asset Management LLC now owns 877,798 shares of the biotechnology company’s stock worth $4,886,000 after acquiring an additional 58,866 shares during the period.

Kamada Company Profile

(Get Rating)

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD.

Featured Stories

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.